Oruka Therapeutics Aktie Logo
US6876041087

Oruka Therapeutics Aktie

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +17,48(+66,48%). Der Median liegt bei +17,48(+66,48%).

Kaufen
  2
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

    MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY:» Mehr auf globenewswire.com


  • Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

    Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care MENLO PARK, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-002, the Company's novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-17A and IL-17F (IL-17A/F).» Mehr auf globenewswire.com


  • Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, Phase 1 initiation accelerated to 2Q 2025, with initial PK data now expected around YE 2025; data will support both ORKA-002 and ORKA-021 psoriasis studies Strong cash position of $373 million provides runway through 2027, over one year past anticipated ORKA-001 Phase 2a data in psoriasis MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported first quarter 2025 financial results and provided a corporate update.» Mehr auf globenewswire.com

Dividenden

Alle Kennzahlen
In 2024 hat Oruka Therapeutics Aktie +1,45 Dividende ausgeschüttet. Die letzte Dividende wurde im August 2024 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Oruka Therapeutics Aktie einen Umsatz von 0,00 und ein Nettoeinkommen von 19,41 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen14,79k15,99%
Nettoeinkommen19,41 Mio942,75%
EBITDA19,40 Mio951,90%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+398,95 Mio
Anzahl Aktien
37,44 Mio
52 Wochen-Hoch/Tief
+45,73 - +4,80
Dividendenrendite
+13,81%
Dividenden TTM
+1,45
Beta
-0,42
KGV (PE Ratio)
6,74
KGWV (PEG Ratio)
0,34
KBV (PB Ratio)
+1,39
KUV (PS Ratio)
0,00

Unternehmensprofil

Name
Oruka Therapeutics Aktie
CEO
Dr. Lawrence Otto Klein Ph.D.
Mitarbeiter28

Ticker Symbole

BörseSymbol
München
HQ1.MU
Frankfurt
HQ1.F
Düsseldorf
HQ1.DU
NASDAQ
ORKA

Assets entdecken

Shareholder von Oruka Therapeutics Aktie investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr